Your browser doesn't support javascript.
loading
MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients.
Olivera, Gladys G; Yáñez, Yania; Gargallo, Pablo; Sendra, Luis; Aliño, Salvador F; Segura, Vanessa; Sanz, Miguel Ángel; Cañete, Adela; Castel, Victoria; Font De Mora, Jaime; Hervás, David; Berlanga, Pablo; Herrero, María José.
Afiliación
  • Olivera GG; Pharmacogenetics Platform, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
  • Yáñez Y; Department of Pharmacology, University of Valencia, 46010 Valencia, Spain.
  • Gargallo P; Clinical and Translational Research in Cancer, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
  • Sendra L; Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Aliño SF; Pharmacogenetics Platform, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
  • Segura V; Department of Pharmacology, University of Valencia, 46010 Valencia, Spain.
  • Sanz MÁ; Pharmacogenetics Platform, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain.
  • Cañete A; Department of Pharmacology, University of Valencia, 46010 Valencia, Spain.
  • Castel V; Clinical Pharmacology Unit, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Font De Mora J; Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Hervás D; Hematology and Hemotherapy Service, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Berlanga P; Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Herrero MJ; Pediatric Oncology Unit, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
Int J Mol Sci ; 21(8)2020 Apr 14.
Article en En | MEDLINE | ID: mdl-32295184
Single nucleotide polymorphisms (SNPs) in Pharmacogenetics can play an important role in the outcomes of the chemotherapy treatment in Neuroblastoma, helping doctors maximize efficacy and minimize toxicity. Employing AgenaBioscience MassArray, 96 SNPs were genotyped in 95 patients looking for associations of SNP with response to induction therapy (RIT) and grade 3-4 toxicities, in High Risk patients. Associations of SNPs with overall (OS) and event-free (EFS) survival in the whole cohort were also explored. Cox and logistic regression models with Elastic net penalty were employed. Association with grade 3-4 gastrointestinal and infectious toxicities was found for 8 different SNPs. Better RIT was correlated with rs726501 AG, rs3740066 GG, rs2010963 GG and rs1143684 TT (OR = 2.87, 1.79, 1.23, 1.14, respectively). EFS was affected by rs2032582, rs4880, rs3814058, rs45511401, rs1544410 and rs6539870. OS was influenced by rs 1801133, rs7186128 and rs1544410. Remarkably, rs1801133 in MTHFR (p = 0.02) and rs1544410 in VDR (p = 0.006) also added an important predictive value for OS to the MYCN status, with a more accurate substratification of the patients. Although validation studies in independent cohorts will be required, the data obtained supports the utility of Pharmacogenetics for predicting Neuroblastoma treatment outcomes.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Receptores de Calcitriol / Metilenotetrahidrofolato Reductasa (NADPH2) / Proteína Proto-Oncogénica N-Myc / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Receptores de Calcitriol / Metilenotetrahidrofolato Reductasa (NADPH2) / Proteína Proto-Oncogénica N-Myc / Neuroblastoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Int J Mol Sci Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Suiza